What is KALV stock price today?

KALV (Kalvista Pharmaceuticals Inc) stock is trading at $19.56 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KALV stock going up or down today?

KALV stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KALV stock now?

The decision to buy KALV depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KALV a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KALV based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KALV stock overvalued or undervalued?

Use our DCF valuation calculator to determine if KALV is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is KALV's P/E ratio?

P/E ratio data for KALV will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is KALV's market cap?

KALV (Kalvista Pharmaceuticals Inc) has a market capitalization of $1.07 billion, making it a small-cap stock.

What is KALV's price to book ratio?

KALV trades at a price-to-book (P/B) ratio of 49.03, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KALV pay dividends?

KALV does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is KALV's dividend yield?

KALV does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is KALV stock a good long-term investment?

KALV's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KALV's revenue growth rate?

KALV has shown revenue growth of 0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

KALV is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in KALV?

Key risks for KALV include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KALV compare to its competitors?

Compare KALV to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KALV's performance and positioning.

What is KALV's stock price target for 2026?

Our AI model provides price targets for KALV based on fundamental analysis: Bull case $25.43 (+30%), Base case $22.49 (+15%), Bear case $17.60 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KALV?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KALV. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KALV's next earnings report?

KALV reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KALV - Kalvista Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$19.56

$-1.30 (-6.23%)

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

KALV Key Statistics

Market Cap

$1.07B

P/B Ratio

49.03

EPS

$-3.94

Revenue Growth

+0.3%

Profit Margin

-2.2%

Employees

275

How KALV Compares to Peers

KALV has the fastest revenue growth among competitors

KALV is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KALV(This stock)	$1.07B	N/A	0%	-2.2%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Kalvista Pharmaceuticals Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.kalvista.com
Sector: Health Care
Industry: Biotechnology

KALV - Kalvista Pharmaceuticals Inc

About Kalvista Pharmaceuticals Inc

KALV Key Statistics

How KALV Compares to Peers

Kalvista Pharmaceuticals Inc Company Information

KALV Lician Score

KALV Financial Snowflake

Upcoming Events for KALV